Day: May 11, 2021

BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “In the first quarter Timber continued to advance on all of its programs.In January, we announced that the Phase 2b CONTROL Study of Congenital Ichthyosis for our lead asset, TMB-001, had reached 50% enrollment. The Company anticipates topline data readout in the third quarter of 2021 for the TMB-001 study. The Phase 2b clinical trial evaluating TMB-002...

CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. The Company is pleased to announce that Jay Roberts, Chief Executive Officer, will present at BioNJ’s 11th Annual BioPartnering Conference. The presentation portion event is being held virtually from May 17-18, 2021. One-on-one partnering meetings will be held throughout the week (May 17-21 2021). An on-demand replay of Vyant Bio’s presentation will be available to registered guests.Conference Date: May 18-19, 2021 (Tuesday-Wednesday)Presentation Time: Tuesday, May 18, 2021...

EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the public offering will be sold by Recro.  Recro is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or...

U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care EU IXCHANGE Phase II trial is fully enrolled with results expected by the end of 2021JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today positive topline results from its U.S. Phase II IXPLORE study with vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis, or AAV. “ANCA-associated vasculitis is an organ and life-threatening disease. Although current treatments for AAV are quite helpful in many patients, there are still unmet needs for fast-acting,...

Virtual Event Highlights II-VI’s Innovation Strategy, Markets, and Technology Platforms Underpinning the Transformation to Mobile, Intelligent, and Electric PITTSBURGH, May 11, 2021 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, announced today that the Company will present a special webcast for investors on Thursday, May 20, 2021, from 10:00 a.m. to 12:00 p.m. ET. The “II-VI Advanced Markets & Technologies” event will feature II-VI’s top leaders presenting insights into the Company’s innovation strategy, markets, and technology platforms. A live Q&A with equity analysts will follow the presentations, beginning at 11:30 a.m., and will be hosted by Dr. Vincent D. (Chuck) Mattera, Jr., CEO; Dr. Giovanni Barbarossa, Chief Strategy Officer and President...

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that President and CEO, Jordan Trimble, will present at the Red Cloud Conference “Uranium: Fueling the Path Towards Electrification”, which will take place virtually on May 13, 2021. Mr. Trimble will provide an overview of Skyharbour’s current activity as an exploration company, together with next steps for the Company’s high-grade uranium exploration projects and prospect generator model in Saskatchewan. Skyharbour PresentationDate: May 13, 2021 Time: 1:40pm ET / 10:40am PT Spokesperson: Jordan Trimble B.SC., CFA, President and CEOInvestors interested in attending the Skyharbour Resources webcast at the event can register here:https://www.redcloudfs.com/uraniumconference2021/ About...

DENVER, May 11, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, will hold a conference call on Friday, May 14, 2021, at 12:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2021. The Company will report its financial results in a press release prior to the conference call. Date: Friday, May 14, 2021Time: 12:00 p.m. Eastern time (10:00 a.m. Mountain time)Toll-free dial-in number: 1-877-407-0792International dial-in number: 1-201-689-8263Conference ID: 13719448 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay here. A replay of the...

Q1 total revenue grew 34% year-over-year to $81.2 million Q1 recurring revenue grew 37% year-over-year to $74.9 million ARR grew 37% year-over-year to $308.0 million as of March 31, 2021MINNEAPOLIS, May 11, 2021 (GLOBE NEWSWIRE) — Jamf (NASDAQ: JAMF), the standard in Apple Enterprise Management, today announced financial results for its first quarter ended March 31, 2021. First Quarter 2021 Financial Highlights:ARR: ARR increased 37% year-over-year to $308.0 million as of March 31, 2021. Revenue: Total revenue was $81.2 million, an increase of 34% year-over-year. Recurring revenue was $74.9 million, an increase of 37% year-over-year. Gross Profit: GAAP gross profit was $63.9 million, or 79% of total revenue, compared to $45.4 million, or 75% of total revenue, in the first quarter of 2020. Non-GAAP Gross Profit was $67.1 million,...

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “Over the past few months, we have made good progress as we advance VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), toward the anticipated submission of the Investigational New Drug (IND) application in order to generate clinical proof-of-concept data,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “While we remain laser-focused on delivering on our VAX-24 milestones, I am also very excited by the progress...